FLT3 recombinant proteins and antibodies

FMS-like tyrosine kinase 3 (FLT3), together with KIT, FMS, and platelet-derived growth factor receptor (PDGFR), belongs to the class III receptor tyrosine kinase (RTK) family and is a single-pass transmembrane protein. FLT3 is a receptor tyrosine kinase that is almost exclusively expressed in the hematopoietic compartment. Its ligand, FL, induces dimerization and activation of its intrinsic tyrosine kinase activity. Upon binding to its ligand FL, FLT3 induces receptor dimerization and autophosphorylation, followed by activation of cell signaling pathways that regulate the proliferation and differentiation of immature hematopoietic cells. Although FL itself is a weak proliferative stimulus, it can synergize with stem cell factor (SCF, a ligand for C-KIT) or other cytokines to enhance the expansion of progenitor cells. More FLT3 signaling pathways >> 

Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematological malignancy, and its occurrence is closely related to a variety of cytogenetic and chromosomal abnormalities. Among them, FLT3 gene mutation is one of the most common genetic changes. Studies have shown that about 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about 10% of patients have FLT3 tyrosine kinase domain mutations (FLT3-TKD). These mutations usually lead to persistent activation of the FLT3 signaling pathway, promote abnormal proliferation of leukemia cells, and are associated with poor prognosis. Although patients with FLT3 mutant AML may achieve transient remission after traditional chemotherapy or hematopoietic stem cell transplantation (HSCT), they have a higher risk of relapse and greater treatment challenges. Therefore, FLT3 has become a key target for AML research and treatment, and targeted treatment strategies for this receptor are constantly developing and optimizing.

To assist in the development of FLT3 targeted drugs, DIMA BIOTECH can now provide a series of FLT3 target spot products, including recombinant proteins, recombinant monoclonal antibodies and biotin/PE labeled antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank for FLT3 targets, which can screen out the lead antibody molecules required by customers in just 20 days. For more details, please contact us.